• Astellas teams with Adaptimmune to create CAR-T, TCR therapies

    11 days ago - By Fierce Biotech

    Astellas has teamed up with Adaptimmune to develop allogeneic chimeric antigen receptor T-cell and T-cell receptor therapies. The agreement sees Astellas pay $50 million upfront and commit to many times as much in milestones to work with Adaptimmune to identify targets and develop cell therapies against them.
    Read more ...